<DOC>
	<DOC>NCT02461316</DOC>
	<brief_summary>Evaluation of safety profile and tolerability of MabThera (rituximab) in combination with chemotherapy (fludarabine and cyclophosphamide) in the treatment of Chronic Lymphocytic Leukemia (CLL).</brief_summary>
	<brief_title>Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Patients older than 18 years with diagnosed Chronic Lymphocytic Leukemia (CLL) CLL stages: Binet stage C (Rai III or IV), Binet stage B (Rai I and II) requiring treatment Patients who are not eligible for rituximab treatment according to Summary of Product Characteristics (SmPC)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>